Join the Pulmonary Embolism group to help and get support from people like you.
Pulmonary Embolism News
Related terms: Pulmonary Emboli
Rate of Venous Thromboembolism Increased With Cancer Surgery
FRIDAY, Feb. 2, 2024 – The rate of venous thromboembolism is increased in association with cancer surgery, according to a study published online Feb. 2 in JAMA Network Open. Johan Björklund, M.D., ...
Little Change Seen in Rates of ED Discharge After Acute Pulmonary Embolism
MONDAY, Jan. 29, 2024 – For patients with acute pulmonary embolism (PE), the rates of discharge from the emergency department were stable between 2012 and 2020, according to a study published online...
Mechanical Thrombectomy Safe, Effective for High-Risk Pulmonary Embolism
FRIDAY, Dec. 1, 2023 – Mechanical thrombectomy (MT) is safe and effective in real-world, high-risk patients with pulmonary embolism (PE), according to a study published online Oct. 31 in the Journal ...
Pulmonary Embolism-Related Mortality Remained Unchanged From 2006 to 2019
FRIDAY, Sept. 8, 2023 – Mortality related to pulmonary embolism (PE) has remained unchanged since 2006 and is higher among men, Black patients, and those living in rural areas, according to a study...
FDA Medwatch Alert: Eliquis (apixaban) 5 mg tablets: Recall One Lot- Bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets
ISSUE: Bristol-Myers Squibb Company is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the U.S. to wholesalers and retail...
FDA Approves Savaysa (edoxaban) to Prevent Embolic Events in Non-Valvular Atrial Fibrillation
January 8, 2015 – The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in...
FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Thursday, August 21, 2014 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug...
FDA Medwatch Alert: Coumadin (warfarin sodium) for Injection by Bristol-Myers Squibb: Recall - Particulate Matter
ISSUE: Bristol-Myers Squibb Company issued a voluntary recall of six lots of Coumadin for Injection, 5 mg single-use vials in the U.S. Visible particulate matter was found in a small number of ...
FDA Approves Pradaxa for Deep Venous Thrombosis and Pulmonary Embolism
Ridgefield, CT, April 7, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for th...
FDA Expands Use of Xarelto to Treat, Reduce Recurrence of Blood Clots
November 2, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Pulmonary Embolism - First Event, Pulmonary Embolism - Recurrent Event